378 related articles for article (PubMed ID: 31385753)
1. Imaging of Precision Therapy for Lung Cancer: Current State of the Art.
Park H; Sholl LM; Hatabu H; Awad MM; Nishino M
Radiology; 2019 Oct; 293(1):15-29. PubMed ID: 31385753
[TBL] [Abstract][Full Text] [Related]
2. Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists.
O'Neill AC; Jagannathan JP; Ramaiya NH
Korean J Radiol; 2017; 18(1):6-17. PubMed ID: 28096714
[TBL] [Abstract][Full Text] [Related]
3. Molecular Characterization and Therapeutic Approaches to Small Cell Lung Cancer: Imaging Implications.
Park H; Tseng SC; Sholl LM; Hatabu H; Awad MM; Nishino M
Radiology; 2022 Dec; 305(3):512-525. PubMed ID: 36283111
[TBL] [Abstract][Full Text] [Related]
4. The Current and Evolving Role of PET in Personalized Management of Lung Cancer.
Mena E; Yanamadala A; Cheng G; Subramaniam RM
PET Clin; 2016 Jul; 11(3):243-59. PubMed ID: 27321029
[TBL] [Abstract][Full Text] [Related]
5. Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives.
Cucchiara F; Petrini I; Romei C; Crucitta S; Lucchesi M; Valleggi S; Scavone C; Capuano A; De Liperi A; Chella A; Danesi R; Del Re M
Pharmacol Res; 2021 Jul; 169():105643. PubMed ID: 33940185
[TBL] [Abstract][Full Text] [Related]
6. Precision radiotherapy for non-small cell lung cancer.
Yang WC; Hsu FM; Yang PC
J Biomed Sci; 2020 Jul; 27(1):82. PubMed ID: 32693792
[TBL] [Abstract][Full Text] [Related]
7. Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.
Nishino M; Hatabu H; Sholl LM; Ramaiya NH
Radiographics; 2017; 37(5):1371-1387. PubMed ID: 28898185
[TBL] [Abstract][Full Text] [Related]
8. Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
Albaba H; Lim C; Leighl NB
Pharmacoeconomics; 2017 Dec; 35(12):1195-1209. PubMed ID: 28861770
[TBL] [Abstract][Full Text] [Related]
9. [Personalized therapy of lung cancer - current standard and future challenges].
Riedel R; Wolf J
Dtsch Med Wochenschr; 2017 Nov; 142(22):1660-1668. PubMed ID: 29078211
[TBL] [Abstract][Full Text] [Related]
10. Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond.
Rajan A; Schrump DS
Semin Thorac Cardiovasc Surg; 2015; 27(1):36-48. PubMed ID: 26074108
[TBL] [Abstract][Full Text] [Related]
11. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
12. Targeted agents in the management of small cell lung cancer - present and future.
Srivastava R; Lebowicz Y; Jamil MO
Drugs Today (Barc); 2018 Aug; 54(8):479-488. PubMed ID: 30209442
[TBL] [Abstract][Full Text] [Related]
13. Biomarker strategy in lung cancer.
Esencay M; Watson A; Mukherjee K; Hanicq D; Gubernick SI
Nat Rev Drug Discov; 2018 Jan; 17(1):13-14. PubMed ID: 28959953
[No Abstract] [Full Text] [Related]
14. Radiomics in Lung Cancer from Basic to Advanced: Current Status and Future Directions.
Lee G; Park H; Bak SH; Lee HY
Korean J Radiol; 2020 Feb; 21(2):159-171. PubMed ID: 31997591
[TBL] [Abstract][Full Text] [Related]
15. [Application strategies of the third-generation EGFR-TKI in the context of precision medicine].
Zhao J; Zhang SJ; Zhou CC
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):86-89. PubMed ID: 28219200
[TBL] [Abstract][Full Text] [Related]
16. [Improving the internal medical care to set up a leading model for precision medicine development in lung cancer].
Han BH
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):81-85. PubMed ID: 28219199
[TBL] [Abstract][Full Text] [Related]
17. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the Breakthroughs in Lung Cancer Treatment.
Oncology (Williston Park); 2020 Dec; 34(12):536-538. PubMed ID: 33395493
[TBL] [Abstract][Full Text] [Related]
19. Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.
Addeo A; Tabbò F; Robinson T; Buffoni L; Novello S
Crit Rev Oncol Hematol; 2018 Feb; 122():150-156. PubMed ID: 29458783
[TBL] [Abstract][Full Text] [Related]
20. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization.
Hensing T; Chawla A; Batra R; Salgia R
Adv Exp Med Biol; 2014; 799():85-117. PubMed ID: 24292963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
